373 related articles for article (PubMed ID: 27037840)
1. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
2. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
3. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
Masarova L; Alhuraiji A; Bose P; Daver N; Pemmaraju N; Cortes J; Pierce S; Kantarjian H; Verstovsek S
Eur J Haematol; 2018 Mar; 100(3):257-263. PubMed ID: 29226426
[TBL] [Abstract][Full Text] [Related]
4. EZH2 mutational status predicts poor survival in myelofibrosis.
Guglielmelli P; Biamonte F; Score J; Hidalgo-Curtis C; Cervantes F; Maffioli M; Fanelli T; Ernst T; Winkelman N; Jones AV; Zoi K; Reiter A; Duncombe A; Villani L; Bosi A; Barosi G; Cross NC; Vannucchi AM
Blood; 2011 Nov; 118(19):5227-34. PubMed ID: 21921040
[TBL] [Abstract][Full Text] [Related]
5. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
Masarova L; Verstovsek S
Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
[TBL] [Abstract][Full Text] [Related]
6. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
[TBL] [Abstract][Full Text] [Related]
7. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.
Ferrer-Marín F; Arroyo AB; Bellosillo B; Cuenca EJ; Zamora L; Hernández-Rivas JM; Hernández-Boluda JC; Fernandez-Rodriguez C; Luño E; García Hernandez C; Kerguelen A; Fiallo-Suárez DV; Gómez-Casares MT; Ayala R; Vélez P; Boqué C; García-Gutierrez V; Arrizabalaga B; Estrada N; Cifuentes R; Arcas I; de Los Reyes-García AM; Besses C; Vicente V; Alvarez-Larrán A; Teruel-Montoya R; González-Conejero R; Martínez C;
Leukemia; 2020 Oct; 34(10):2648-2659. PubMed ID: 32107471
[TBL] [Abstract][Full Text] [Related]
8. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
9. Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.
Kandarpa M; Robinson D; Wu YM; Qin T; Pettit K; Li Q; Luker G; Sartor M; Chinnaiyan A; Talpaz M
Clin Cancer Res; 2024 May; 30(9):1972-1983. PubMed ID: 38386293
[TBL] [Abstract][Full Text] [Related]
10. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
11. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
12. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Tefferi A; Lasho TL; Abdel-Wahab O; Guglielmelli P; Patel J; Caramazza D; Pieri L; Finke CM; Kilpivaara O; Wadleigh M; Mai M; McClure RF; Gilliland DG; Levine RL; Pardanani A; Vannucchi AM
Leukemia; 2010 Jul; 24(7):1302-9. PubMed ID: 20508616
[TBL] [Abstract][Full Text] [Related]
13. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
Martínez-Trillos A; Maffioli M; Colomer D; Alvarez-Larrán A; Pereira A; Angona A; Bellosillo B; Cervantes F
Ann Hematol; 2014 May; 93(5):797-802. PubMed ID: 24337516
[TBL] [Abstract][Full Text] [Related]
15. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
16. Genetic Risk Assessment in Myeloproliferative Neoplasms.
Tefferi A; Vannucchi AM
Mayo Clin Proc; 2017 Aug; 92(8):1283-1290. PubMed ID: 28778261
[TBL] [Abstract][Full Text] [Related]
17. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
[TBL] [Abstract][Full Text] [Related]
18. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
19. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of outcome in MPN.
Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
